AI in Genomics Market: as transformer foundation models collapse the cost of interpreting a genome to below the cost of sequencing it, AI shifts from a research convenience into the rate-limiting step in clinical genomics, so diagnostic laboratories are re-architecting around AI-native interpretation pipelines, and platform vendors that combine sequencing scale with proprietary variant-interpretation models are capturing a widening share of downstream diagnostic and drug-discovery revenue.

The global AI in genomics market size was USD 1.24 Billion in 2025 and is expected to register a revenue CAGR of 27.4% during the forecast period. Market revenue growth is driven by factors such as the collapse of whole-genome sequencing costs alongside the arrival of transformer-based foundation models for variant interpretation, the expansion of national genomics programmes generating diverse annotated training datasets, and the growing pharmaceutical use of AI-interpreted genomic data for drug target identification. The first driving factor is the falling cost of sequencing colliding with the arrival of foundation models capable of interpreting genomic data at clinical speed. Whole-genome sequencing costs fell below USD 500 per genome, and each sequence generates 200 to 300 gigabytes of raw data, a volume the National Human Genome Research Institute projects will reach 2 to 40 billion exabytes globally over the next decade, a scale that exceeds manual analytical capacity by orders of magnitude and makes AI interpretation the only feasible pathway to clinical-grade genomic insight. The second driving factor is the emergence of large, diverse, AI-training-grade genomic datasets from national sequencing programmes. Genomics England’s 100,000 Genomes Project and the NIH All of Us Research Program, which reached more than 750,000 enrolled participants in 2024 with a majority from historically underrepresented groups, are supplying the multi-ancestry annotation depth that AI variant interpretation models require to generalise beyond narrow training populations. The third driving factor is the pharmaceutical industry’s adoption of AI-interpreted genomic data for target identification and biomarker discovery. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single AI-interpreted comprehensive genomic profiling platform widens its own revenue base as new companion diagnostic indications are added to an already-approved assay, which lets one cleared platform capture incremental pharmaceutical and payer revenue without a new clinical trial for each therapy. Once a genomic profiling platform earns its first companion diagnostic approval, each additional indication added to the same underlying assay adds new billable claims without requiring the platform itself to be re-validated from scratch, so the value of an approved comprehensive genomic profiling platform compounds as the pharmaceutical pipeline of targeted therapies referencing it grows around it. As a result, demand and revenue share are concentrating around platforms that hold the broadest base of approved companion diagnostic indications, and the forecast tilts toward comprehensive, indication-agnostic profiling platforms rather than single-biomarker tests. For instance, in December 2025, Foundation Medicine, United States, reached 100 approved and active companion diagnostic indications across its FoundationOne CDx and FoundationOne Liquid CDx platforms, one of more than fifty United States indications the same underlying assay now carries without a new platform validation for each. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the simultaneous collapse of sequencing cost and the arrival of foundation models capable of genome-wide variant interpretation. Cheaper sequencing works as a demand multiplier only if interpretation keeps pace, and interpretation increasingly requires models trained at genome-wide scale, so falling sequencing cost and rising foundation-model capability are arriving together rather than independently. The World Intellectual Property Organization documented that whole-genome sequencing costs had fallen below USD 500 per genome, with projections indicating the cost could reach USD 10 per genome within years, a trajectory that converts whole-genome sequencing into a routine clinical diagnostic for cancer profiling, rare disease diagnosis, and pharmacogenomic drug selection. The recent record shows the pace. In September 2023, Google DeepMind, United Kingdom, announced an AI system for identifying disease-causing changes in human DNA capable of predicting variant pathogenicity at genome-wide scale, and in January 2026 Illumina secured Medicare reimbursement for its FDA-approved TruSight Oncology Comprehensive genomic profiling test, extending AI-interpreted comprehensive genomic profiling into standard clinical reimbursement pathways. The effect on the market is that AI interpretation speed, not sequencing throughput, is becoming the binding constraint on how quickly genomic data converts into clinical or commercial value. These are some of the key factors driving revenue growth of the market.

The second driver is the buildout of national sequencing programmes purpose-built to train and validate AI variant interpretation models across diverse populations. AI genomic interpretation models trained on narrow demographic samples fail to generalise to underrepresented populations, and closing that gap requires national-scale sequencing infrastructure rather than incremental research cohorts, so government-funded genomics programmes have become the primary supply channel for AI training data. Genomics England’s 100,000 Genomes Project produced the largest single national whole-genome sequencing clinical dataset in the world, and the NIH All of Us Research Program reached more than 750,000 enrolled participants in 2024 with a majority from historically underrepresented groups, materially narrowing the demographic bias documented in earlier AI genomic variant interpretation studies. In October 2024, the Genome of Europe project launched to build a European network of national genomic reference cohorts from more than 100 academic institutions and national healthcare systems, and SeqOne’s September 2025 acquisition of Congenica combined AI sequencing analytics with a curated rare-disease clinical variant library, with the combined platform processing more than 200,000 patient genomic analyses in 2025. The effect on the market is that AI variant interpretation accuracy for rare and non-European-ancestry populations is improving fast enough to expand the clinically addressable use cases for AI genomics beyond common-variant contexts. These are some of the key factors driving revenue growth of the market.

“The NIH All of Us Research Program’s more than 750,000 enrolled participants, a majority from historically underrepresented groups, is the single largest correction to AI genomic interpretation’s demographic bias problem to date. Every model trained against that cohort inherits a materially wider population base than the research datasets that preceded it.”

The third driver is the pharmaceutical industry’s adoption of AI-interpreted genomic datasets as a standard input into drug target identification and biomarker discovery. AI target-identification models require genomic datasets linked to phenotypic and outcomes data at a scale no single pharmaceutical company can generate alone, and multi-company data-sharing consortia increasingly substitute for internally generated cohorts, so co-funded sequencing initiatives are becoming the default acquisition model for AI-ready genomic data in pharma. Illumina’s Alliance for Genomic Discovery, a collaborative initiative announced in July 2023 involving AbbVie, AstraZeneca, Bayer, Merck, and other major pharmaceutical companies co-funding whole-genome sequencing of 250,000 diverse samples for drug target discovery, demonstrated the scale of pharma investment in AI-interpretable genomic datasets. Amgen’s deCODE genetics used NVIDIA’s BioNeMo computing platform in 2024 to develop large-scale genomic models for biomarker and target discovery, representing the pharmaceutical industry’s adoption of foundation-model-scale genomic AI for drug target prioritisation at institutional scale. The effect on the market is that pharmaceutical co-funded sequencing consortia are becoming a durable, repeatable revenue channel for AI genomics platform vendors rather than a one-time data purchase. These are some of the key factors driving revenue growth of the market.

However, the AI in genomics market faces severe adoption constraints from uneven training-data annotation quality and the regulatory complexity of clinical validation for AI-based genomic interpretation tools. Because AI genomic variant interpretation model performance is bounded by the annotation quality and demographic diversity of its training dataset, a 2025 study in npj Genomic Medicine documented substantial discordance between AlphaMissense pathogenicity predictions and clinical-grade expert curation in a rare disease cohort, achieving only 32.9% precision for expert-curated pathogenic variants, so AI genomics tools optimised for common variant pathogenicity prediction perform significantly worse on the rare, novel, and splice-altering variants that constitute the majority of clinically actionable findings in rare disease diagnostic sequencing. Regulatory validation burden is a second constraint, because the FDA’s 2024 draft guidance on AI and machine learning-based Software as a Medical Device applied to genomic diagnostic software requires analytical and clinical validation studies demonstrating diagnostic accuracy across diverse patient populations and variant classes before a tool can generate clinically reportable variant interpretations, and this compliance burden limits commercial deployment to the subset of vendors that have completed 510(k) clearance or laboratory-developed test validation under CLIA. Data privacy and multi-institutional sharing friction is the third constraint, since the GDPR Article 9 restrictions on processing genomic data as a special category of personal data in European Union member states prevent European clinical sequencing laboratories from contributing patient genomic datasets to multi-institutional AI training consortia without complex data-processing agreements that are difficult to establish retrospectively for historical sequencing datasets, so the cost of assembling diverse, consented training data is not always recovered, and laboratories without dedicated regulatory affairs capacity struggle to participate in AI model generalisation efforts. These factors substantially limit AI in genomics market growth over the forecast period.

Based on technology, the global AI in genomics market is segmented into machine learning, deep learning, natural language processing, and computer vision. Machine learning holds the largest revenue share, because it is established in genomic variant calling, genome-wide association study analysis, and drug target prioritisation across pharmaceutical and clinical genomics applications, which suits its lower validation burden relative to newer foundation-model approaches. Natural language processing and computer vision remain established for automated report generation and cytogenetic imaging respectively, and they are cheaper to deploy for a single narrow use case, but they cannot match machine learning’s breadth of validated clinical and pharmaceutical applications. Deep learning is expected to register the fastest revenue growth rate in the global AI in genomics market over the forecast period, driven by the commercial deployment of transformer foundation models such as Google DeepMind’s genomic variant AI and NVIDIA’s BioNeMo framework, which is why Illumina and Tempus AI are migrating their flagship comprehensive genomic profiling platforms onto foundation-model architectures.

Based on application, the global AI in genomics market is segmented into drug discovery and target identification, clinical diagnostics and variant interpretation, personalised medicine and treatment selection, genome sequencing and bioinformatics, and agrigenomics and population genomics. Drug discovery and target identification holds the largest revenue share, because it generates the highest absolute revenue per deployment through multi-year pharmaceutical platform subscription contracts, which suits the industry’s shift toward co-funded sequencing consortia over one-time data purchases. Personalised medicine and treatment selection is expected to register rapid revenue growth in the global AI in genomics market over the forecast period, driven by comprehensive genomic profiling platforms adding companion diagnostic indications faster than new tests can be independently validated, which is why Foundation Medicine and Tempus AI are expanding indication counts on their existing FDA-cleared platforms rather than launching new assays.

Based on end-user, the global AI in genomics market is segmented into pharmaceutical and biotechnology companies, research institutions and academic centres, healthcare providers and clinical laboratories, and government and regulatory agencies. Pharmaceutical and biotechnology companies hold the largest revenue share, reflecting large data-partnership investments, drug discovery platform subscriptions, and AI-enabled clinical trial design and biomarker workflow fees, which suits the multi-year contract structure that AI genomics vendors have built their commercial models around. Healthcare providers and clinical laboratories are expected to register rapid revenue growth in the global AI in genomics market over the forecast period, driven by Medicare and private-payer reimbursement decisions extending to more AI-interpreted comprehensive genomic profiling tests, which is why Illumina’s TruSight Oncology Comprehensive and Tempus AI’s xT and xR assays are converting from research-only to reimbursed clinical use.

Based on regional analysis, the AI in genomics market in North America accounted for largest revenue share in 2025. The United States leads because it is home to the largest concentration of AI genomics companies globally, including Illumina, Foundation Medicine, GRAIL, Tempus AI, Guardant Health, and Myriad Genetics, and because the country’s NIH-funded research infrastructure, including All of Us and the Cancer Genome Atlas, sustains the highest AI genomics research investment of any region. Illumina secured Medicare reimbursement for its TruSight Oncology Comprehensive genomic profiling test in January 2026, a coverage decision that strengthens the commercial foundation for AI-interpreted comprehensive genomic profiling across the entire United States clinical laboratory market. The concentration of FDA-cleared AI genomics platforms in the United States also means new companion diagnostic indications are often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national AI genomics markets within Europe. The UK’s Genomics England NHS Genomic Medicine Service represents the world’s largest national health system deployment of AI-assisted clinical genomic interpretation, and the Genome of Europe project, launched in October 2024 with more than 100 participating institutions, is building the pan-European genomic reference infrastructure that AI variant interpretation across Southern, Eastern, and Scandinavian populations depends on. The European Medicines Agency’s companion diagnostic co-review framework moves more slowly than the FDA’s single-agency pathway, and the region’s GDPR Article 9 data protection regime adds a further layer of multi-institutional data-sharing friction. The result is steady rather than rapid growth, shaped more by regulatory and data-sharing structure than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national AI genomics markets within the region. China’s government-backed AI healthcare investment programme and its Five-Year Plan targets for domestic AI industry expansion are sustaining Chinese AI genomics platform development, while Japan’s ageing population is driving government investment in genomics-based personalised medicine and South Korea’s biotechnology infrastructure provides a further anchor for regional AI genomics adoption. The region’s comparatively lower installed base of FDA-cleared or CE-marked AI genomic interpretation platforms leaves more room for growth than in the more saturated North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national AI genomics markets within the region. Brazil’s public genomics research infrastructure and private clinical sequencing laboratories offering AI-assisted variant interpretation represent the primary AI genomics commercial infrastructure in the region, and access remains concentrated in metropolitan academic medical centres. The indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised sequencing instruments and AI compute hardware that Latin American genomics laboratories depend on through 2026, and this cost pressure slows AI genomics adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial AI genomics markets within the GCC. Saudi Arabia’s Saudi Human Genome Program, which has sequenced more than 100,000 Saudi genomes since its launch, represents the largest national genomics dataset in the Arab world and the primary AI genomics data infrastructure for developing population-specific variant interpretation models. Saudi Arabia is the most established AI genomics market on the continent, while the wider Gulf states outside the Kingdom are still building clinical sequencing and AI interpretation capacity from scratch.